Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA)-induced OA rat model

Abstract Background Osteoarthritis (OA) is the most common type of degenerative arthritis and affects the entire joint, causing pain, joint inflammation, and cartilage damage. Various risk factors are implicated in causing OA, and in recent years, a lot of research and interest have been directed to...

Full description

Bibliographic Details
Main Authors: Hyun Sik Na, Seon-Yeong Lee, Dong Hwan Lee, Jin Seok Woo, Si-Young Choi, Keun-Hyung Cho, Seon Ae Kim, Eun Jeong Go, A Ram Lee, Jeong-Won Choi, Seok Jung Kim, Mi-La Cho
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Journal of Translational Medicine
Online Access:https://doi.org/10.1186/s12967-022-03515-3
_version_ 1811264911043461120
author Hyun Sik Na
Seon-Yeong Lee
Dong Hwan Lee
Jin Seok Woo
Si-Young Choi
Keun-Hyung Cho
Seon Ae Kim
Eun Jeong Go
A Ram Lee
Jeong-Won Choi
Seok Jung Kim
Mi-La Cho
author_facet Hyun Sik Na
Seon-Yeong Lee
Dong Hwan Lee
Jin Seok Woo
Si-Young Choi
Keun-Hyung Cho
Seon Ae Kim
Eun Jeong Go
A Ram Lee
Jeong-Won Choi
Seok Jung Kim
Mi-La Cho
author_sort Hyun Sik Na
collection DOAJ
description Abstract Background Osteoarthritis (OA) is the most common type of degenerative arthritis and affects the entire joint, causing pain, joint inflammation, and cartilage damage. Various risk factors are implicated in causing OA, and in recent years, a lot of research and interest have been directed toward chronic low-grade inflammation in OA. Monocyte chemoattractant protein-1 (MCP-1; also called CCL2) acts through C–C chemokine receptor type 2 (CCR2) in monocytes and is a chemotactic factor of monocytes that plays an important role in the initiation of inflammation. The targeting of CCL2–CCR2 is being studied as part of various topics including the treatment of OA. Methods In this study, we evaluated the potential therapeutic effects the sCCR2 E3 gene may exert on OA. The effects of sCCR2 E3 were investigated in animal experiments consisting of intra-articular injection of sCCR2 E3 in a monosodium iodoacetate (MIA)-induced OA rat model. The effects after intra-articular injection of sCCR2 E3 (fusion protein encoding 20 amino acids of the E3 domain of the CCL2 receptor) in a monosodium iodoacetate-induced OA rat model were compared to those in rats treated with empty vector (mock treatment) and full-length sCCR2. Results Pain improved with expression of the sCCR2 gene. Improved bone resorption upon sCCR2 E3 gene activation was confirmed via bone analyses using micro-computed tomography. Histologic analyses showed that the sCCR2 E3 gene exerted protective effects against cartilage damage and anti-inflammatory effects on joints and the intestine. Conclusions These results show that sCCR2 E3 therapy is effective in reducing pain severity, inhibiting cartilage destruction, and suppressing intestinal damage and inflammation. Thus, sCCR2 E3 may be a potential therapy for OA.
first_indexed 2024-04-12T20:13:08Z
format Article
id doaj.art-aff8b875ec8142c199f8a20511cd3f2a
institution Directory Open Access Journal
issn 1479-5876
language English
last_indexed 2024-04-12T20:13:08Z
publishDate 2022-09-01
publisher BMC
record_format Article
series Journal of Translational Medicine
spelling doaj.art-aff8b875ec8142c199f8a20511cd3f2a2022-12-22T03:18:12ZengBMCJournal of Translational Medicine1479-58762022-09-0120111210.1186/s12967-022-03515-3Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA)-induced OA rat modelHyun Sik Na0Seon-Yeong Lee1Dong Hwan Lee2Jin Seok Woo3Si-Young Choi4Keun-Hyung Cho5Seon Ae Kim6Eun Jeong Go7A Ram Lee8Jeong-Won Choi9Seok Jung Kim10Mi-La Cho11Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of KoreaLab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of KoreaDepartment of Orthopedic Surgery, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of KoreaLab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of KoreaLab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of KoreaLab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of KoreaDepartment of Orthopedic Surgery, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of KoreaDepartment of Orthopedic Surgery, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of KoreaLab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of KoreaLab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of KoreaDepartment of Orthopedic Surgery, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of KoreaLab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of KoreaAbstract Background Osteoarthritis (OA) is the most common type of degenerative arthritis and affects the entire joint, causing pain, joint inflammation, and cartilage damage. Various risk factors are implicated in causing OA, and in recent years, a lot of research and interest have been directed toward chronic low-grade inflammation in OA. Monocyte chemoattractant protein-1 (MCP-1; also called CCL2) acts through C–C chemokine receptor type 2 (CCR2) in monocytes and is a chemotactic factor of monocytes that plays an important role in the initiation of inflammation. The targeting of CCL2–CCR2 is being studied as part of various topics including the treatment of OA. Methods In this study, we evaluated the potential therapeutic effects the sCCR2 E3 gene may exert on OA. The effects of sCCR2 E3 were investigated in animal experiments consisting of intra-articular injection of sCCR2 E3 in a monosodium iodoacetate (MIA)-induced OA rat model. The effects after intra-articular injection of sCCR2 E3 (fusion protein encoding 20 amino acids of the E3 domain of the CCL2 receptor) in a monosodium iodoacetate-induced OA rat model were compared to those in rats treated with empty vector (mock treatment) and full-length sCCR2. Results Pain improved with expression of the sCCR2 gene. Improved bone resorption upon sCCR2 E3 gene activation was confirmed via bone analyses using micro-computed tomography. Histologic analyses showed that the sCCR2 E3 gene exerted protective effects against cartilage damage and anti-inflammatory effects on joints and the intestine. Conclusions These results show that sCCR2 E3 therapy is effective in reducing pain severity, inhibiting cartilage destruction, and suppressing intestinal damage and inflammation. Thus, sCCR2 E3 may be a potential therapy for OA.https://doi.org/10.1186/s12967-022-03515-3
spellingShingle Hyun Sik Na
Seon-Yeong Lee
Dong Hwan Lee
Jin Seok Woo
Si-Young Choi
Keun-Hyung Cho
Seon Ae Kim
Eun Jeong Go
A Ram Lee
Jeong-Won Choi
Seok Jung Kim
Mi-La Cho
Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA)-induced OA rat model
Journal of Translational Medicine
title Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA)-induced OA rat model
title_full Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA)-induced OA rat model
title_fullStr Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA)-induced OA rat model
title_full_unstemmed Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA)-induced OA rat model
title_short Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA)-induced OA rat model
title_sort soluble ccr2 gene therapy controls joint inflammation cartilage damage and the progression of osteoarthritis by targeting mcp 1 in a monosodium iodoacetate mia induced oa rat model
url https://doi.org/10.1186/s12967-022-03515-3
work_keys_str_mv AT hyunsikna solubleccr2genetherapycontrolsjointinflammationcartilagedamageandtheprogressionofosteoarthritisbytargetingmcp1inamonosodiumiodoacetatemiainducedoaratmodel
AT seonyeonglee solubleccr2genetherapycontrolsjointinflammationcartilagedamageandtheprogressionofosteoarthritisbytargetingmcp1inamonosodiumiodoacetatemiainducedoaratmodel
AT donghwanlee solubleccr2genetherapycontrolsjointinflammationcartilagedamageandtheprogressionofosteoarthritisbytargetingmcp1inamonosodiumiodoacetatemiainducedoaratmodel
AT jinseokwoo solubleccr2genetherapycontrolsjointinflammationcartilagedamageandtheprogressionofosteoarthritisbytargetingmcp1inamonosodiumiodoacetatemiainducedoaratmodel
AT siyoungchoi solubleccr2genetherapycontrolsjointinflammationcartilagedamageandtheprogressionofosteoarthritisbytargetingmcp1inamonosodiumiodoacetatemiainducedoaratmodel
AT keunhyungcho solubleccr2genetherapycontrolsjointinflammationcartilagedamageandtheprogressionofosteoarthritisbytargetingmcp1inamonosodiumiodoacetatemiainducedoaratmodel
AT seonaekim solubleccr2genetherapycontrolsjointinflammationcartilagedamageandtheprogressionofosteoarthritisbytargetingmcp1inamonosodiumiodoacetatemiainducedoaratmodel
AT eunjeonggo solubleccr2genetherapycontrolsjointinflammationcartilagedamageandtheprogressionofosteoarthritisbytargetingmcp1inamonosodiumiodoacetatemiainducedoaratmodel
AT aramlee solubleccr2genetherapycontrolsjointinflammationcartilagedamageandtheprogressionofosteoarthritisbytargetingmcp1inamonosodiumiodoacetatemiainducedoaratmodel
AT jeongwonchoi solubleccr2genetherapycontrolsjointinflammationcartilagedamageandtheprogressionofosteoarthritisbytargetingmcp1inamonosodiumiodoacetatemiainducedoaratmodel
AT seokjungkim solubleccr2genetherapycontrolsjointinflammationcartilagedamageandtheprogressionofosteoarthritisbytargetingmcp1inamonosodiumiodoacetatemiainducedoaratmodel
AT milacho solubleccr2genetherapycontrolsjointinflammationcartilagedamageandtheprogressionofosteoarthritisbytargetingmcp1inamonosodiumiodoacetatemiainducedoaratmodel